Oslo, Norway, 15 March 2023 - Targovax ASA (OSE: TRVX) today announces that an
abstract describing its circular RNA platform has been accepted for poster
presentation at the 2023 American Association for Cancer Research (AACR) Annual
Meeting in Orlando, USA.

The abstract describes the advantage of protein expression utilizing
TargovaxŽproprietary circAde vector system. By comparing protein expression from
circRNA and mRNA-based vectors, it is shown that the circAde-system out-performs
conventional mRNA-based designs, both in terms of protein expression level and
durability. Persistent and prolonged protein expression in patients correlate
with positive treatment outcome. The results thus highlight the circAde
platform's potential for development of novel, more effective medicines for the
treatment of cancer and other diseases.

The abstract has been released on the AACR website
(https://www.abstractsonline.com/pp8/#!/10828/presentation/5271). The poster is
scheduled for presentation Tuesday 18 April 2022 and will be available on
Targovax's website (https://www.targovax.com/en/oncos-oncolytic-virus
-publications-posters-and-oral-presentations/) after the presentation.

Poster      circAde: a circRNA-based system for prolonged
title:      and more effective treatment of cancer
Date and    Tuesday 18 April 2023, 13:30- 17:00 CDT /
time:       20:30-24:00 CET
Location:   Orange County Convention Center, Orlando,
            Florida
Session     High-throughput Screening, Lead Identification
title:      and Optimization, and in Silico Drug Discovery
Poster      5335 / 17
number:
Presenter:  Thomas Birkballe Hansen, VP Research, Targovax

About AACR

The AACR Annual Meeting is the focal point of the cancer research community,
where scientists, clinicians, other health care professionals, survivors,
patients, and advocates gather to share the latest advances in cancer science
and medicine. From population science and prevention